Minister initiates stakeholder meeting to address current medicines shortage

"No shortage of alternative medicines available"

by Rose Barrett
0 comment

The Minister for Health Stephen Donnelly TD has welcomed a multi-stakeholder meeting to discuss ongoing efforts to minimize the impact of medicines shortages currently being experienced in Ireland and across the EU.

The meeting between industry, health sector and patient representatives, officials from the Department of Health and the Health Products Regulatory Authority took place yesterday, Friday January 20. 

Minister Donnelly said: “At my request, the Department of Health held a multistakeholder event to listen to the experiences of all parties, to update on work ongoing to manage this situation and to discuss any further potential actions deemed appropriate during this period”.

Stephen Donnelly, Minister for Health

He stated he was looking forward to hearing the outcome of yesterday’s meeting and ensuring all suitable actions are progressed.

“I wish to acknowledge the ongoing work by all stakeholders in the management of medicines shortages at present. The Medicines Shortages Framework, operated by the Health Product Regulatory Authority (HPRA) on behalf of my Department, aims to prevent, where possible, and mitigate the impact of medicines shortages when they occur through timely communication with stakeholders. The current situation is being coordinated by the HPRA through this framework in close collaboration with my Department, the HSE, industry and healthcare professionals.” 

The Minister added: “I would particularly like to commend the valuable contribution being made by our prescribers and pharmacists who are working closely together in ensuring best outcomes for patients in accessing medicines at this time.”

Due to the high levels of respiratory illnesses and increased numbers of persons presenting with Covid-19 in recent weeks, a significant increase in demand for medicines used to treat seasonal conditions such as colds and flus has been observed. Demand in some cases is two to three times the typical demand seen normally at this time of year.  

The issue is mirrored across EU countries. The European Commission along with the European Medicines Agency (EMA) are working on a suite of measures to tackle the immediate issues as well as looking to implement long-term, sustainable solutions to ensure continuity of supply to the EU market.

Whilst there are currently many products listed as being in short supply on the HPRA website, there are typically multiple alternatives available from various sources and suitable substitutes continue to be available on the market to treat respiratory illnesses.

Of all products out of stock at this time the Department can confirm that there are none for which there is no suitable clinical alternative. 

Furthermore, contrary to some industry claims, the Department can confirm that no company has cited pricing as a reason for current product shortages.   To support this the HSE completed a comprehensive review of the published HPRA shortages list on 16 January 2023. Of all products listed in short supply, none were attributable to pricing issues. 

Through close engagement with industry, the HPRA has confirmed that in several instances suppliers have increased production and sourced additional stock to respond to this recent increase in demand. The HPRA remains open to expediting regulatory procedures to enable supply of additional stock, where possible. 

The HSE has established an Incident Management Team (IMT) to address shortages of antibiotics and has issued several memos to support prescribers and pharmacists at this time. Working closely with the HPRA, they have developed a webpage to include information on products currently available (

Related Articles